<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="9130">Sevoflurane</z:chebi> preconditioning has recently been demonstrated to protect ischemic brain in vivo and in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>However, mechanisms underlying this neuroprotection have not been delineated </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore assessed the hypothesis that <z:chebi fb="0" ids="9130">sevoflurane</z:chebi> pretreatment protected blood-brain-barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) via suppression of cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules (CAMs) and matrix metalloproteinases (MMPs) after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Repeated <z:chebi fb="0" ids="9130">sevoflurane</z:chebi> preconditioning was administered 24 hours before transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="4" pm="."><plain>Neurologic deficits and expression of CAMs, MMPs and occludin were examined up to 3 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Evans blue (EB) extravasation and electron microscopy was detected at 2 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The data showed that <z:chebi fb="0" ids="9130">sevoflurane</z:chebi> pretreatment markedly improved <z:chebi fb="2" ids="33602">BBB</z:chebi> integrity and neurological outcomes after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, robustly suppressed <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced decreases of occludin and increases of intracellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (ICAM-1), vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (VCAM-1), MMP-2, MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="9130">Sevoflurane</z:chebi> pretreatment also suppressed the activation of astrocytes and microglias in ipsilateral cortex and corpus callosum </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, repeated <z:chebi fb="0" ids="9130">sevoflurane</z:chebi> preconditioning confered potent protection against <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>, partly by improving <z:chebi fb="2" ids="33602">BBB</z:chebi> integrity </plain></SENT>
</text></document>